The Top 5 VC deals of the first half of 2007

Venture capital is the lifeblood of up-and-coming biotechs. In order to interest investors and keep the money coming in, biotechs must have a strong vision, promising pipeline and a management team that can guide a company through the rigorous drug development process. For a look at which biotechs have gained the most attention this year, check out the five promising companies that raised the most money in the first half of 2007.

 

Ception Therapeutics

Targanta Therapeutics

  Portola Pharmaceuticals

Novexel

Movetis

 

The Top 5 VC deals of the first half of 2007
Read more on

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.